From: Hyperglycemia related to high-dose glucocorticoid use in noncritically ill patients
Variable | CGC n =12 | CyGC n = 20 | P^ |
---|---|---|---|
Baseline | |||
Insulin (pmol/L) | 64.59 ± 17.36 | 53.48 ± 18.75 | 0.12 |
HOMA-IR | 2.2 ± 0.79 | 1.73 ± 0.79 | 0.11 |
HOMA (β-cell) | 112.8 ± 47.8 | 113.3 ± 63.2 | 0.98 |
Insulin, follow-up week (pmol/L) | |||
1 | 105.56 ± 66.67 | - | - |
2 | 125.70 ± 75.01 | - | - |
3 | 142.37 ± 57.64 | 106.95 ± 59.73 | 0.11 |
4 | 154.87 ± 88.20 | - | - |
5 | 156.96 ± 86.81 | - | - |
6 | 169.46 ± 109.73 | 125.70 ± 73.62 | 0.19 |
8 | 129.87 ± 68.75 | - | - |
9 | - | 120.15 ± 70.84 | - |
12 | - | 96.53 ± 40.28 | - |
Insulin (pmol/L) [n] | |||
With DM1 | 63.20 ± 15.97 | 61.46 ± 20.14 | 0.88 |
Without DM2 | 66.67 ± 21.32 | 51.39 ± 18.75 | 0.15 |
P value (1 vs. 2) | 0.75 | 0.39 | - |
HOMA-IR | |||
With DM3 | 2.20 ± 0.74 | 2.14 ± 0.96 | 0.91 |
Without DM4 | 2.21 ± 0.94 | 1.62 ± 0.75 | 0.17 |
P value (3 vs.4) | 0.99 | 0.35 | - |
HOMA- β-cell | |||
With DM5 | 98.8 ± 21.9 | 135.3 ± 102 | 0.36 |
Without DM6 | 132 ± 68.9 | 107 ± 53.1 | 0.40 |
p value (5 vs.6) | 0.24 | 0.45 | - |
MMII† pmol/L(%) | |||
With DM [week]7 | 145.84(231%) [6] | 154.18(251%) [9] | 0.76 |
Without DM [week]8 | 82.64 (116%) [4] | 56.25 (111%) [6] | 0.37 |
p value (7 vs. 8) | 0.02* | 0.01* | - |